What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Telomere Syndrome: Causes, Symptoms, and Molecular Mechanisms

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Telomere Syndrome

Telomere syndrome is a collective term for a group of inherited disorders caused by mutations in genes involved in telomere maintenance, resulting in critically short telomeres and premature cellular aging. The condition is also referred to as short telomere syndrome or telomeropathy. Rather than a single disease, telomere syndrome encompasses a clinical spectrum that includes dyskeratosis congenita, idiopathic pulmonary fibrosis, bone marrow failure, and liver cirrhosis, among others. The unifying feature is defective telomere biology, which leads to progressive loss of replicative capacity in highly proliferative tissues.

What Are Telomeres?

Telomeres are repetitive nucleotide sequences—TTAGGG in vertebrates—located at the ends of linear chromosomes. They serve as protective caps that distinguish natural chromosome ends from double-strand DNA breaks, preventing inappropriate DNA damage responses and end-to-end fusion. In humans, telomeres span 10–15 kilobases at birth and shorten by 50–200 base pairs per cell division due to the end-replication problem: DNA polymerase cannot fully replicate the 3′ end of linear DNA. For a detailed treatment of this process, see Telomere Shortening.

When telomeres reach a critical length threshold—approximately 4–5 kilobases—they trigger a persistent DNA damage response, leading to cellular senescence or apoptosis. This mechanism acts as a tumor suppressor barrier but also contributes to organismal aging. The relationship between telomere attrition and aging phenotypes is explored further in Telomere Aging.

The Spectrum of Telomere Syndromes

Telomere syndrome presents across a continuum of severity, largely determined by the specific gene mutated and the residual function of the encoded protein. The most severe form, dyskeratosis congenita (DC), typically manifests in childhood with the classic triad of nail dystrophy, reticular skin pigmentation, and oral leukoplakia. Hoyeraal-Hreidarsson syndrome is a severe variant of DC that additionally includes cerebellar hypoplasia, immunodeficiency, and intrauterine growth restriction.

At the milder end of the spectrum, adults may present with isolated pulmonary fibrosis or unexplained bone marrow failure without the classic mucocutaneous features. This variable expressivity means that family members carrying the same mutation can have vastly different clinical presentations, ranging from asymptomatic to life-threatening organ failure. The recognition that a single genetic defect can produce such diverse phenotypes has reshaped how clinicians approach patients with unexplained bone marrow failure or pulmonary fibrosis.

Telomere Biology and Maintenance

Understanding telomere syndrome requires a thorough grasp of normal telomere biology, including the structural organization of telomeres and the enzymatic machinery that maintains them.

Telomere Structure and Function

Telomeres consist of tandem hexameric repeats (TTAGGG) that are predominantly double-stranded, with a single-stranded G-rich 3′ overhang of 50–300 nucleotides. This overhang invades the double-stranded region to form a lasso-like structure called a T-loop, which is stabilized by the shelterin protein complex. The T-loop sequesters the chromosome end, preventing activation of the ATM and ATR DNA damage kinases.

The shelterin complex comprises six core proteins: TRF1 and TRF2 (which bind double-stranded telomeric DNA), POT1 (which binds the single-stranded overhang), TPP1 (which recruits telomerase), TIN2 (which bridges TRF1/TRF2 to TPP1/POT1), and RAP1 (which interacts with TRF2). Shelterin not only protects chromosome ends but also regulates telomerase access and telomere length homeostasis.

Telomeres also contain noncoding telomeric RNA (TERRA) transcribed from the C-rich strand, which contributes to heterochromatin formation and telomere length regulation. The structural details of the telomere–chromosome interface are described in Telomere Chromosome.

Telomerase and Its Components

Telomerase is a ribonucleoprotein enzyme that counteracts telomere shortening by adding TTAGGG repeats to chromosome ends. It consists of two essential components: the telomerase reverse transcriptase catalytic subunit (TERT) and the telomerase RNA component (TERC), which serves as the template for nucleotide addition. The enzyme also requires accessory proteins, including dyskerin (encoded by DKC1), NOP10, NHP2, and GAR1, which stabilize TERC and are essential for telomerase assembly and function.

Telomerase is highly active in germ cells, embryonic stem cells, and activated lymphocytes, but its expression is repressed in most somatic tissues. This repression explains why telomeres shorten with each cell division in normal somatic cells. The catalytic cycle of telomerase involves binding to the 3′ overhang, reverse transcribing the RNA template to add six nucleotides, translocating, and repeating the process. For a step-by-step account, see Telomere Replication.

The regulation of telomerase activity is complex. The TERT promoter contains binding sites for multiple transcription factors, including c-MYC and Sp1, which activate transcription. Epigenetic modifications, including DNA methylation and histone acetylation at the TERT promoter, also influence expression. Post-translationally, TERT is phosphorylated by Akt and PKC, which affects its nuclear localization and catalytic activity.

Alternative Lengthening of Telomeres (ALT)

A subset of cancers and immortalized cell lines maintain telomere length through a recombination-based mechanism called alternative lengthening of telomeres (ALT). ALT cells are characterized by the presence of ALT-associated promyelocytic leukemia (PML) bodies, which contain telomeric DNA, shelterin proteins, and recombination factors. The ALT pathway relies on homologous recombination between telomeric sequences, using a sister chromatid or another chromosome as a template.

ALT is not a normal physiological mechanism in human somatic cells, but understanding it is relevant to telomere syndrome because some patients with telomere dysfunction may show evidence of ALT activation as a compensatory response. However, ALT does not rescue the phenotype in telomere syndrome patients, likely because the underlying defect is not merely telomere length but also telomere structure and protection.

Genetic Causes of Telomere Syndrome

Telomere syndrome is genetically heterogeneous, with mutations identified in at least 14 genes encoding components of telomerase, shelterin, and telomere-associated proteins. These mutations reduce telomerase activity or disrupt telomere protection, leading to accelerated telomere shortening.

Mutations in Telomerase Components

The most commonly mutated genes in telomere syndrome are TERT and TERC, which account for approximately 10–15% of familial pulmonary fibrosis and 5–10% of dyskeratosis congenita cases. Mutations in TERT are typically missense mutations that reduce but do not eliminate reverse transcriptase activity. In contrast, TERC mutations often involve deletions or point mutations in conserved regions of the RNA that disrupt template usage or RNA stability.

DKC1 mutations cause X-linked dyskeratosis congenita, the most severe form of the disease. Dyskerin is a pseudouridine synthase that modifies ribosomal RNA, but its role in telomere maintenance involves stabilizing TERC. Mutations in DKC1 dramatically reduce TERC levels and telomerase activity, explaining the severe phenotype. Because DKC1 is on the X chromosome, males are predominantly affected, while female carriers show variable phenotypes due to X-inactivation.

Other telomerase-associated genes include NOP10, NHP2, and TCAB1 (also known as WRAP53). These genes encode proteins required for telomerase assembly, trafficking, and localization to Cajal bodies. Mutations in these genes are rare but cause autosomal recessive dyskeratosis congenita.

Mutations in Shelterin Complex Proteins

Shelterin gene mutations are less common but cause distinct clinical features. TINF2 mutations, which affect the TIN2 protein, cause autosomal dominant dyskeratosis congenita and are among the most severe mutations, often presenting in early childhood with bone marrow failure. TIN2 is critical for stabilizing the shelterin complex, and mutations disrupt the interaction between TRF1, TRF2, and TPP1.

POT1 mutations have been identified in familial melanoma and, more recently, in some patients with telomere syndrome features. POT1 binds the single-stranded telomeric overhang and regulates telomerase access. Loss-of-function POT1 mutations lead to telomere lengthening rather than shortening in some contexts, but can also cause telomere uncapping and DNA damage signaling.

Mutations in RTEL1, a helicase that resolves T-loops and prevents telomere recombination, cause a severe form of Hoyeraal-Hreidarsson syndrome. RTEL1 deficiency leads to telomere loss and the formation of telomeric circles (T-circles) due to aberrant homologous recombination.

Inheritance Patterns and Penetrance

Telomere syndrome follows autosomal dominant, autosomal recessive, and X-linked inheritance patterns, depending on the gene involved. TERT and TERC mutations are typically autosomal dominant with incomplete penetrance and variable expressivity. This means that not all carriers develop symptoms, and the age of onset and severity vary widely, even within the same family.

The phenomenon of genetic anticipation—where disease severity increases and age of onset decreases in successive generations—is observed in telomere syndrome. This occurs because telomere length is inherited: a child inherits not only the mutated gene but also the already-shortened telomeres from the affected parent. Each generation inherits progressively shorter telomeres, leading to earlier and more severe disease. This is a critical concept for genetic counseling, as it explains why a grandparent may have mild pulmonary fibrosis while a grandchild presents with severe bone marrow failure in childhood.

Clinical Manifestations and Associated Diseases

The clinical presentation of telomere syndrome reflects the tissues with the highest proliferative demand: bone marrow, lungs, liver, and skin. The age of onset and predominant organ involvement vary with the specific genetic defect and telomere length.

Pulmonary Fibrosis

Pulmonary fibrosis is the most common adult manifestation of telomere syndrome, accounting for 8–15% of familial pulmonary fibrosis cases. Patients typically present between ages 40 and 60 with progressive dyspnea, dry cough, and restrictive lung physiology on pulmonary function testing. High-resolution computed tomography shows usual interstitial pneumonia (UIP) pattern with peripheral reticulation, traction bronchiectasis, and honeycombing in the lung bases.

The pathogenesis involves alveolar epithelial cell senescence. Type II pneumocytes, which are responsible for surfactant production and alveolar repair, undergo premature senescence when telomeres become critically short. This impairs the regenerative capacity of the alveolar epithelium, leading to progressive fibrosis. The rate of decline in lung function is variable, but the median survival after diagnosis is approximately 3–5 years without transplantation.

Bone Marrow Failure and Dyskeratosis Congenita

Bone marrow failure is the hallmark of dyskeratosis congenita and is the leading cause of death in affected children. The bone marrow becomes progressively hypocellular as hematopoietic stem cells (HSCs) exhaust their replicative capacity. Patients develop cytopenias—anemia, thrombocytopenia, and neutropenia—in any combination, with thrombocytopenia often appearing first.

The classic triad of dyskeratosis congenita—nail dystrophy, reticular skin pigmentation, and oral leukoplakia—typically appears by age 10. Nail changes include ridging, splitting, and eventual loss of nails. Skin pigmentation appears as a lace-like pattern on the neck, chest, and upper arms. Oral leukoplakia presents as white patches on the buccal mucosa and tongue, with a significant risk of malignant transformation to squamous cell carcinoma.

Patients with dyskeratosis congenita also have a markedly increased risk of developing cancers, particularly squamous cell carcinoma of the head, neck, and anogenital region. The cumulative incidence of cancer by age 50 is approximately 40–50%, reflecting the genomic instability caused by telomere dysfunction.

Other Organ Systems Affected

Liver disease is increasingly recognized as a manifestation of telomere syndrome. Patients may develop cryptogenic cirrhosis, nonalcoholic steatohepatitis-like histology, or hepatopulmonary syndrome. Liver fibrosis progresses silently, and many patients are diagnosed only when they present with portal hypertension or hepatocellular carcinoma.

Gastrointestinal involvement includes enteropathy with villous atrophy, leading to malabsorption and failure to thrive in children. Immunodeficiency is common, particularly in Hoyeraal-Hreidarsson syndrome, with low B-cell and T-cell counts and hypogammaglobulinemia. Neurological features include cerebellar hypoplasia, ataxia, and developmental delay in severe cases.

Other reported manifestations include avascular necrosis of the femoral head, osteoporosis, dental anomalies, and retinopathy. The multisystem nature of telomere syndrome means that patients require coordinated care across multiple specialties.

Diagnosis and Testing

The diagnosis of telomere syndrome requires a combination of clinical suspicion, telomere length measurement, and genetic testing. Early diagnosis is essential because it informs prognosis, screening for complications, and family counseling.

Telomere Length Measurement

Telomere length is most commonly measured by flow cytometry with fluorescence in situ hybridization (flow-FISH) on peripheral blood leukocytes. This technique uses a peptide nucleic acid probe complementary to the telomeric repeat sequence and quantifies telomere length in specific cell populations, including lymphocytes and granulocytes. Results are reported as telomere length in kilobases or as a percentile compared to age-matched controls.

Telomere length below the first percentile for age in multiple leukocyte subsets is considered diagnostic of telomere syndrome. Importantly, telomere length should be interpreted in the context of age, as telomeres shorten normally with aging. A 60-year-old patient with telomeres at the 10th percentile may have telomere syndrome, whereas a 5-year-old with the same absolute telomere length would be severely affected.

Quantitative PCR (qPCR) is an alternative method that measures the ratio of telomeric repeats to a single-copy gene (T/S ratio). This method requires less blood and is cheaper but provides less precise information about cell-type-specific telomere length. For a comprehensive overview of testing approaches, see Telomere Testing.

Genetic Testing and Counseling

Genetic testing should be offered to all patients with clinical features of telomere syndrome and confirmatory short telomeres. A targeted panel that includes TERT, TERC, DKC1, TINF2, RTEL1, NOP10, NHP2, and other known genes is the most efficient approach. If the panel is negative, whole-exome or whole-genome sequencing may identify mutations in novel genes.

Genetic counseling is essential because of the autosomal dominant inheritance with anticipation. Family members of affected individuals should be offered clinical evaluation and telomere length testing, even if asymptomatic. Prenatal testing and preimplantation genetic diagnosis are options for families with identified pathogenic mutations.

One challenge in genetic testing is the interpretation of variants of uncertain significance. Many TERT and TERC variants are rare and may not have clear functional data. In such cases, telomere length measurement in multiple family members can help establish whether a variant segregates with short telomeres and disease.

Molecular Mechanisms of Disease Pathogenesis

The clinical manifestations of telomere syndrome arise from a cascade of cellular events triggered by critically short telomeres. Understanding these mechanisms is essential for developing targeted therapies.

Cellular Senescence and Apoptosis

When telomeres become critically short, the single-stranded overhang is lost, and the T-loop structure becomes destabilized. This exposes the chromosome end, which is recognized as a double-strand break by the DNA damage response machinery. The MRN complex (MRE11-RAD50-NBS1) and ATM kinase are activated, leading to phosphorylation of CHK2 and p53. Phosphorylated p53 upregulates p21, a cyclin-dependent kinase inhibitor, which arrests the cell cycle in G1 phase.

This arrest is termed replicative senescence and is characterized by a flattened cell morphology, increased senescence-associated β-galactosidase activity, and secretion of pro-inflammatory cytokines known as the senescence-associated secretory phenotype (SASP). SASP factors, including IL-6, IL-8, and matrix metalloproteinases, create a pro-inflammatory microenvironment that damages surrounding tissues and promotes fibrosis.

If p53 is inactivated or the DNA damage signal is excessive, cells may instead undergo apoptosis. In tissues with high turnover, such as the bone marrow, apoptosis of stem and progenitor cells leads to depletion of the regenerative pool.

Stem Cell Exhaustion

The most critical consequence of telomere shortening is stem cell exhaustion. Hematopoietic stem cells, intestinal crypt stem cells, and alveolar type II cells all require telomerase to maintain their self-renewal capacity. In telomere syndrome, telomerase activity is insufficient to maintain telomere length across many divisions, so stem cells progressively lose telomere length and eventually enter senescence.

The bone marrow is particularly vulnerable because HSCs divide throughout life to maintain blood cell production. When HSCs exhaust, the marrow becomes hypocellular, and peripheral blood counts decline. The rate of decline is influenced by the residual telomerase activity: patients with DKC1 mutations have near-zero telomerase activity and develop bone marrow failure in childhood, while patients with TERT mutations retain partial activity and may not develop cytopenias until adulthood.

Mitochondrial Dysfunction and DNA Damage Response

Recent evidence indicates that telomere dysfunction also affects mitochondrial function. Short telomeres activate p53, which represses PGC-1α and PGC-1β, master regulators of mitochondrial biogenesis. This leads to reduced mitochondrial mass, decreased oxidative phosphorylation, and increased reactive oxygen species (ROS) production. Elevated ROS further damage telomeric DNA, creating a vicious cycle of telomere shortening and oxidative stress.

The DNA damage response at dysfunctional telomeres also activates the innate immune response through the cGAS-STING pathway. Cytosolic DNA fragments released from damaged telomeres bind cGAS, which synthesizes cyclic GMP-AMP (cGAMP) and activates STING, leading to type I interferon production. Chronic interferon signaling contributes to inflammation and tissue damage in telomere syndrome.

Treatment and Management Strategies

There is currently no cure for telomere syndrome, but several treatment strategies can slow disease progression and manage complications. The choice of treatment depends on the predominant organ involvement and disease severity.

Supportive Care and Monitoring

All patients with telomere syndrome require regular monitoring of blood counts, liver function, and pulmonary function. Annual screening for pulmonary fibrosis with pulmonary function tests and high-resolution CT is recommended, as early detection allows for timely intervention. Patients should also undergo regular skin and oral mucosa examinations for early detection of squamous cell carcinoma.

Immunizations, including pneumococcal and influenza vaccines, are important given the increased infection risk. Patients should avoid smoking and exposure to pulmonary irritants, as these can accelerate lung damage.

Androgen Therapy

Androgens, particularly danazol and oxymetholone, have been shown to stimulate telomerase activity and improve hematopoiesis in some patients with telomere syndrome. Danazol, a synthetic androgen, has been reported to increase telomere length and improve blood counts in patients with TERT or TERC mutations. The mechanism involves androgen receptor-mediated upregulation of TERT expression in hematopoietic stem cells.

A typical danazol regimen is 200–400 mg twice daily, with dose adjustment based on response and side effects. Common adverse effects include liver enzyme elevation, fluid retention, and virilization in women. Androgen therapy is not effective in all patients, particularly those with severe bone marrow failure or DKC1 mutations.

Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for bone marrow failure in telomere syndrome. However, it is associated with significant morbidity and mortality, particularly in patients with pulmonary fibrosis or liver disease. Reduced-intensity conditioning regimens are preferred because they cause less organ toxicity than myeloablative conditioning.

The timing of HSCT is critical. Patients with severe cytopenias, transfusion dependence, or recurrent infections should be considered for transplantation early, before the development of end-organ damage. The 5-year survival after HSCT for dyskeratosis congenita is approximately 50–70%, with pulmonary complications being the leading cause of death.

For patients with pulmonary fibrosis, lung transplantation is the only definitive treatment. However, patients with telomere syndrome have worse outcomes after lung transplantation than those with other causes of pulmonary fibrosis, primarily due to higher rates of primary graft dysfunction, cytopenias, and renal failure. The decision to transplant requires careful multidisciplinary evaluation.

Emerging Therapies and Clinical Trials

Several novel therapeutic approaches are under investigation. Gene therapy using lentiviral vectors to deliver functional TERT or DKC1 to hematopoietic stem cells is being explored in preclinical models. The challenge is achieving sufficient gene correction without causing telomerase overexpression, which could promote cancer.

Telomerase activators, such as TA-65, a cycloastragenol derivative, have been studied for their ability to lengthen telomeres in vitro and in animal models. However, clinical evidence for their efficacy in telomere syndrome is limited, and they are not currently recommended.

Small-molecule inhibitors of the p53 pathway, such as the MDM2 inhibitor nutlin-3a, are being investigated for their ability to prevent p53-mediated senescence in telomere-deficient cells. The rationale is that blocking p53 activation might allow cells to continue dividing despite short telomeres, but this approach carries a theoretical risk of promoting genomic instability and cancer.

Common Pitfalls and Misconceptions

Several common errors occur when studying or diagnosing telomere syndrome. Being aware of these pitfalls is essential for accurate understanding and clinical practice.

Misinterpreting Telomere Length Variability

A frequent mistake is assuming that a single telomere length measurement is diagnostic. Telomere length varies significantly among individuals of the same age due to genetic and environmental factors. A measurement at the 5th percentile does not definitively indicate telomere syndrome, nor does a measurement at the 50th percentile exclude it. Serial measurements showing accelerated telomere attrition over time are more informative than a single measurement.

Another error is comparing telomere length across different cell types without adjustment. Granulocytes have shorter telomeres than lymphocytes because they derive from more differentiated progenitors. Flow-FISH results should be compared to age-specific reference ranges for each cell type.

Overlooking Genetic Heterogeneity

Students and clinicians sometimes assume that all telomere syndrome cases are caused by TERT or TERC mutations. In reality, mutations in at least 14 genes can cause the condition, and a significant proportion of patients have no identifiable mutation. The absence of a mutation in a known gene does not rule out telomere syndrome, particularly in sporadic cases.

Additionally, the same gene can cause different phenotypes. TERT mutations can cause pulmonary fibrosis in one family member and bone marrow failure in another. This variable expressivity is often overlooked, leading to delayed diagnosis in family members who present with atypical features.

Confusing Telomere Syndrome with Other Aging Disorders

Telomere syndrome is sometimes conflated with normal aging or with other premature aging disorders such as Werner syndrome or Hutchinson-Gilford progeria syndrome. While all involve accelerated aging phenotypes, the molecular mechanisms are distinct. Werner syndrome is caused by mutations in the WRN helicase, which is involved in DNA repair and replication, not telomere maintenance. Hutchinson-Gilford progeria is caused by a lamin A splice mutation that disrupts nuclear architecture.

Telomere syndrome is specifically defined by mutations in telomere biology genes and is characterized by short telomeres. Other aging disorders may have normal telomere length. The distinction matters for genetic counseling and treatment, as the management strategies differ.

Frequently Asked Questions

What is telomere syndrome?

Telomere syndrome is a group of inherited disorders caused by mutations in genes involved in telomere maintenance, leading to critically short telomeres and premature cellular aging. It encompasses a spectrum of conditions, including dyskeratosis congenita, pulmonary fibrosis, bone marrow failure, and liver disease.

What are the symptoms of telomere syndrome?

Symptoms depend on the affected organs. Common features include bone marrow failure with anemia, thrombocytopenia, and neutropenia; pulmonary fibrosis with progressive shortness of breath; liver cirrhosis; nail dystrophy; skin pigmentation; oral leukoplakia; and increased cancer risk. The age of onset ranges from childhood to late adulthood.

How is telomere syndrome diagnosed?

Diagnosis is based on clinical features, telomere length measurement by flow-FISH showing telomeres below the first percentile for age, and genetic testing identifying mutations in telomere-related genes. A multidisciplinary evaluation including hematology, pulmonology, and genetics is recommended.

Is telomere syndrome inherited?

Yes, telomere syndrome is inherited. It can follow autosomal dominant, autosomal recessive, or X-linked patterns depending on the gene. Autosomal dominant inheritance with anticipation—worsening disease in successive generations—is common with TERT and TERC mutations.

What is the life expectancy of someone with telomere syndrome?

Life expectancy varies widely. Patients with severe dyskeratosis congenita and bone marrow failure in childhood may die in their teens or twenties without transplantation. Patients with adult-onset pulmonary fibrosis have a median survival of 3–5 years after diagnosis without lung transplantation. Milder cases may have near-normal life expectancy.

Can telomere syndrome be cured?

There is no cure, but hematopoietic stem cell transplantation can cure bone marrow failure, and lung transplantation can treat pulmonary fibrosis. Androgen therapy can improve blood counts in some patients. Gene therapy and telomerase activators are under investigation.

What is the difference between telomere syndrome and normal aging?

In normal aging, telomeres shorten gradually over decades, and the rate of shortening is influenced by lifestyle factors such as stress, smoking, and diet. In telomere syndrome, telomere shortening is accelerated due to genetic mutations, leading to premature organ dysfunction at a younger age. Telomere syndrome is a disease with a defined genetic cause, whereas normal aging is a universal biological process. For more on the distinction, see Telomere Health and Telomere Length.

Key Takeaways

Telomere syndrome is caused by mutations in genes encoding telomerase components (TERT, TERC, DKC1) or shelterin proteins (TINF2, POT1), leading to critically short telomeres.
The clinical spectrum ranges from severe childhood dyskeratosis congenita to adult-onset pulmonary fibrosis, with bone marrow failure, liver cirrhosis, and cancer as major complications.
Telomere length below the first percentile for age, measured by flow-FISH, is a key diagnostic criterion, supported by genetic testing.
Inheritance is typically autosomal dominant with anticipation, where each generation inherits shorter telomeres and develops earlier, more severe disease.
Cellular senescence, stem cell exhaustion, and mitochondrial dysfunction are the core pathogenic mechanisms linking short telomeres to organ failure.
Treatment options include androgen therapy, hematopoietic stem cell transplantation for bone marrow failure, and lung transplantation for pulmonary fibrosis, but there is no cure.
Telomere syndrome is distinct from normal aging and other premature aging disorders, and accurate diagnosis requires careful interpretation of telomere length and genetic data.